Literature DB >> 10385643

Outcome of Budd-Chiari syndrome: a multivariate analysis of factors related to survival including surgical portosystemic shunting.

G Zeitoun1, S Escolano, A Hadengue, N Azar, M El Younsi, A Mallet, M J Boudet, J M Hay, S Erlinger, J P Benhamou, J Belghiti, D Valla.   

Abstract

The aim of this study was to assess the factors, including surgical portosystemic shunts, which affect survival in adults with Budd-Chiari syndrome. Multivariate retrospective analysis was performed using characteristics recorded at the time of diagnosis in 120 patients admitted from 1970 to 1992, of whom 82 were treated with surgical portosystemic shunts and 38 received only medical therapy. The 1-, 5-, and 10-year survival rates were 77 +/- 4%, 64 +/- 5%, and 57 +/- 6%, respectively. Survival was significantly better in the subgroup of patients diagnosed after versus before 1985. In both subgroups, and in patients with, as well as in patients without surgical shunts, 4 factors were found to be inversely and independently related to survival: age, response of ascites to diuretics, Pugh score, and serum creatinine. In patients diagnosed since 1985, an index combining these 4 factors allowed to differentiate patients with a good outcome (5-year survival 95%) from those with a poor outcome (5-year survival 62%; P <.05). There was no statistically significant and independent influence of surgical portosystemic shunts on survival. In conclusion, age, severity of liver failure, and presence of refractory ascites are the main prognostic factors in Budd-Chiari syndrome. Increased survival in recent years is consistent with improved management of hypercoagulable states as well as improved general care. It is uncertain whether surgical portosystemic shunting favorably modifies survival. Therefore, we recommend that surgical shunting should be restricted to management of refractory ascites or variceal bleeding in patients with otherwise good prognostic factors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10385643     DOI: 10.1002/hep.510300125

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  37 in total

Review 1.  Splanchnic vein thrombosis: clinical presentation, risk factors and treatment.

Authors:  Valerio De Stefano; Ida Martinelli
Journal:  Intern Emerg Med       Date:  2010-06-08       Impact factor: 3.397

2.  Budd-Chiari syndrome: outcomes of endovascular intervention-A single-center experience.

Authors:  Nitin Jagtap; Mithun Sharma; Jagdeesh Singh; Manu Tandan; P N Rao; Rajesh Gupta; Sundeep Lakhtakia; Mohan Ramchandani; Harshal Shah; T Mahesh Kumar; Santosh Darishetty; G V Rao; D N Reddy
Journal:  Indian J Gastroenterol       Date:  2017-06-20

3.  Favourable medium term outcome following hepatic vein recanalisation and/or transjugular intrahepatic portosystemic shunt for Budd Chiari syndrome.

Authors:  C E Eapen; D Velissaris; M Heydtmann; B Gunson; S Olliff; E Elias
Journal:  Gut       Date:  2005-09-20       Impact factor: 23.059

4.  Prognosis in Budd Chiari syndrome after re-establishing hepatic venous drainage.

Authors:  D-C Valla
Journal:  Gut       Date:  2006-06       Impact factor: 23.059

5.  Aetiological factors of Budd-Chiari syndrome in Algeria.

Authors:  Nawel Afredj; Nawal Guessab; Abdelbasset Nani; Sid Ahmed Faraoun; Ibtissem Ouled Cheikh; Rafik Kerbouche; Djouhar Hannoun; Zine Charef Amir; Hayet Ait Kaci; Kamel Bentabak; Aurélie Plessier; Dominique-Charles Valla; Valerie Cazals-Hatem; Marie-Hélène Denninger; Tadjeddine Boucekkine; Nabil Debzi
Journal:  World J Hepatol       Date:  2015-04-28

6.  Management of Budd-Chiari syndrome.

Authors:  Joachim Ruh; Massimo Malagó; Yasmin Busch; Hauke Lang; Andreas Paul; Rüdiger Verhagen; Christoph E Broelsch
Journal:  Dig Dis Sci       Date:  2005-03       Impact factor: 3.199

7.  Venous thromboembolic disease.

Authors:  Michael B Streiff; Paula L Bockenstedt; Spero R Cataland; Carolyn Chesney; Charles Eby; John Fanikos; Patrick F Fogarty; Shuwei Gao; Julio Garcia-Aguilar; Samuel Z Goldhaber; Hani Hassoun; Paul Hendrie; Bjorn Holmstrom; Kimberly A Jones; Nicole Kuderer; Jason T Lee; Michael M Millenson; Anne T Neff; Thomas L Ortel; Judy L Smith; Gary C Yee; Anaadriana Zakarija
Journal:  J Natl Compr Canc Netw       Date:  2011-07-01       Impact factor: 11.908

8.  Treatment of Budd-Chiari syndrome with a focus on transjugular intrahepatic portosystemic shunt.

Authors:  Anders Bay Neumann; Stine Degn Andersen; Dennis Tønner Nielsen; Peter Holland-Fischer; Hendrik Vilstrup; Henning Grønbæk
Journal:  World J Hepatol       Date:  2013-01-27

Review 9.  Current use of transjugular intrahepatic portosystemic shunts.

Authors:  Timothy M McCashland
Journal:  Curr Gastroenterol Rep       Date:  2003-02

Review 10.  Etiology and consequences of thrombosis in abdominal vessels.

Authors:  Yusuf Bayraktar; Ozgur Harmanci
Journal:  World J Gastroenterol       Date:  2006-02-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.